Javier Velazquez-Gutierrez

Mr. Javier Velazquez-Gutierrez

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JMJorge Melones-Herrero
Jorge Melones-Herrero
PAPatricia Delgado Aliseda
Patricia Delgado Aliseda
SFSofia Figueiras
Sofia Figueiras
JVJavier Velazquez-Gutierrez
Javier Velazquez-Gutierrez
AQAdoracion Gomez Quiroga
Adoracion Gomez Quiroga
ISIsabel Sánchez-Pérez
Isabel Sánchez-Pérez
Gastric cancer prognosis is still notably poor despite efforts made to improve diagnosis and treatment of the disease. Chemotherapy based on platinum agents is generally used, regardless of the fact that drug toxicity leads to limited clinical efficacy. In order to overcome these problems, our group has been working on the synthesis and study of trans platinum (II) complexes. Here, we explore the potential use of two phosphine-based agents with the general formula trans-[Pt(amine)Cl2(PPh3)], called P1 and P2 (with dimethylamine or isopropylamine, respectively). A cytotoxicity analysis showed that P1 and especially P2 decrease cell viability. Specifically, P2 exhibits higher activity than cisplatin in gastric cancer cells while its toxicity in healthy cells is slightly lower. Both complexes generate Reactive Oxygen Species, produce DNA damage and mitochondrial membrane depolarization, and finally lead to induced apoptosis. Thus, an intrinsic apoptotic pathway emerges as the main type of cell death through the activation of BAX/BAK and BIM and the degradation of MCL1. Additionally, we demonstrate here that P2 produces endoplasmic reticulum stress and activates the Unfolded Protein Response, which also relates to the impairment observed in autophagy markers such as p62 and LC3. Although further studies in other biological models are needed, these results report the biomolecular mechanism of action of these Pt(II)-phosphine prototypes, thus highlighting their potential as novel and effective therapies.

29 August 2025 in Analytical Chemistry
Verified
Journal Article
Closed access
ACAndrea Cabrero-Martín
Andrea Cabrero-Martín
VMVíctor Ruiz-Valdepeñas Montiel
Víctor Ruiz-Valdepeñas Montiel
RTRebeca M. Torrente-Rodríguez
Rebeca M. Torrente-Rodríguez
EPEloy Povedano
Eloy Povedano
JVJavier Velazquez-Gutierrez
Javier Velazquez-Gutierrez
SCSusana Campuzano
Susana Campuzano

17 April 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MGMaría Garranzo-Asensio
María Garranzo-Asensio
ECElisa Carral-Ibarra
Elisa Carral-Ibarra
AMAna Montero-Calle
Ana Montero-Calle
MCMarta Gómez de Cedrón
Marta Gómez de Cedrón
JVJavier Velazquez-Gutierrez
Javier Velazquez-Gutierrez
RBRodrigo Barderas
Rodrigo Barderas
Neurochondrin (NCDN) has been recently identified as overexpressed in liver metastatic colorectal cancer (CRC) cells compared to poorly metastatic isogenic counterparts. While its cellular function and role in cancer and CRC remain unknown, patient survival data indicate that elevated NCDN levels are associated with poor prognosis. After validating these observations in an independent patient cohort, we sought to investigate the role of NCDN in CRC progression using isogenic CRC cell models comprising poorly metastatic KM12C and liver-metastatic KM12SM cells, and poorly metastatic SW480 and lymph node-metastatic SW620 cells. Stable silencing of NCDN expression in these cell lines resulted in a significant reduction in their tumorigenic and metastatic properties in vitro. Furthermore, in vivo assays using nude mice and the KM12 cell model demonstrated that NCDN is essential for tumor initiation, growth, and liver metastasis of CRC cells. Proteomic profiling of NCDN-silenced cells uncovered a set of dysregulated proteins associated with cell adhesion, invasion, cell death, and differentiation, and mitochondrial dysfunction, emerging NCDN-PODXL-EZR axis as a critical mediator of CRC progression and involved in liver metastasis. Our findings position NCDN and their associated dysregulated proteins as drivers of CRC progression and promising targets for further investigation.

13 August 2026 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
ACAndrea Cabrero‐Martín
Andrea Cabrero‐Martín
VMVíctor Ruiz‐Valdepeñas Montiel
Víctor Ruiz‐Valdepeñas Montiel
JVJavier Velazquez-Gutierrez
Javier Velazquez-Gutierrez
ACAna Montero Calle
Ana Montero Calle
MGMaría Garranzo‐Asensio
María Garranzo‐Asensio
SCSusana Campuzano
Susana Campuzano

11 August 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
ACAndrea Cabrero‐Martín
Andrea Cabrero‐Martín
VMVíctor Ruiz‐Valdepeñas Montiel
Víctor Ruiz‐Valdepeñas Montiel
JVJavier Velazquez-Gutierrez
Javier Velazquez-Gutierrez
ACAna Montero Calle
Ana Montero Calle
MGMaría Garranzo‐Asensio
María Garranzo‐Asensio
SCSusana Campuzano
Susana Campuzano